Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, March 04 2022 - 11:01
AsiaNet
Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
GENEVA, March 4, 2022 /PRNewswire-AsiaNet/ --

To mark International HPV Awareness Day March 4th 2022, the International 
Papillomavirus Society (IPVS) has warmly welcomed two major advances in the 
elimination of cervical and anal cancers.

HPV (human papillomavirus) is associated with 630,000 cancer diagnoses around 
the world. Almost all cases of cervical and anal cancers are caused by HPV.  
These cancers lead to 470,000 deaths, over 300,000 of which are due to cervical 
cancer.  Current tools for the prevention of HPV-related cancers are: 
vaccination for girls and boys; cervical screening and the treatment of 
cervical pre-cancers in women.

Vaccination of young adolescents with two vaccine doses has been the 
recommended standard of care for several years. However, the UK Government's 
Joint Commission on Vaccination and Immunization has just issued interim advice 
recommending a shift to a single dose schedule. 

The proposed change has been warmly welcomed by IPVS President Prof Suzanne 
Garland, who said, "The evidence that a single dose vaccine schedule for HPV 
offers a high degree of protection against the types of HPV that cause cancer 
is now clear. The benefits of this, in terms of logistics, workforce and costs 
represent a potential game-changer, particularly for low- and middle-income 
countries. One less jab and the elimination of cervical cancer within a 
generation would really mean one less worry for the world."

Another significant recent breakthrough in the prevention of HPV-related cancer 
is the ANCHOR study into anal cancer prevention which has found that 
pre-cancerous changes in the anus can be treated to halt progression of anal 
cancer in a similar way to cervical cancer. Over 50,000 people are diagnosed 
with anal cancer each year.

Trial lead Dr Joel Palefsky said, "Almost all cases of cervical and anal cancer 
are caused by HPV and while vaccination provides a first line of defense, for 
many people who either missed out on vaccination, or who simply aren't covered 
by local vaccination policies, there has been no effective tool to prevent anal 
cancer.  It is exciting that, for the first time, we have clear evidence of an 
approach that could reduce anal cancer for both men and women."  Dr Palefsky 
and his team will be working with various professional organizations to 
translate these results into standard of care guidelines where possible.

Notes to Editors
1.	International Papillomavirus Society: IPVS is the only organization 
dedicated to support of research and public health initiatives related to 
papillomaviruses IPVS - Who We Are [https://ipvsoc.org/who-we-are/  ] 
(ipvsoc.org) 

2.	International HPV Awareness Day: On March 4th around 120 organisations 
deliver events and activities to raise awareness of HPV. Find out more about 
the One Less Worry Campaign at AskAboutHPV.org [ https://www.askabouthpv.org/ 
]. 

3.	Sources 
a.	COVID-19 and cervical cancer - A pandemic's impact and a global response  [ 
https://ncdalliance.org/news-events/blog/covid-19-and-cervical-cancer-a-pandemic%25E2%2580%2599s-impact-and-a-global-response 
]
b.	Sharp Declines in Breast and Cervical Cancer Screening  [ 
https://www.cdc.gov/media/releases/2021/p0630-cancer-screenings.html#:~:text=The%2520decline%2520for%2520cervical%2520cancer,end%2520of%2520the%2520observation%2520period. 
]
c.	Single Dose of HPV Vaccine Yields Long-Term Protection from Many 
Cancer-Causing Types  [ 
https://www.cancer.gov/news-events/cancer-currents-blog/2020/hpv-vaccine-single-dose-long-term-protection 
]
d.	JCVI interim advice on a one-dose schedule for the routine HPV immunisation 
programme  [ 
https://www.gov.uk/government/publications/single-dose-of-hpv-vaccine-jcvi-interim-advice/jcvi-interim-advice-on-a-one-dose-schedule-for-the-routine-hpv-immunisation-programme 
]
e.	Treating Anal Cancer Precursor Lesions Reduces Cancer Risk for People With 
HIV [ 
https://www.ucsf.edu/news/2021/10/421591/treating-anal-cancer-precursor-lesions-reduces-cancer-risk-people-hiv#:~:text=In%2520a%2520randomized%2520clinical%2520trial,anal%2520cancer%2520were%2520significantly%2520reduced. 
]

Spokespeople
Professor Suzanne Garland, IPVS President, Professor of Reproductive & Neonatal 
Infectious Diseases, Department of Obstetrics and Gynaecology, and Director of 
the Women's Centre for Infectious Diseases in Melbourne. Regular advisor to the 
World Health Organisation (WHO) on sexual and reproductive health, cervical 
cancer and HPV. 

Dr. Joel Palefsky, founder and chairperson of the IPVS International HPV 
Awareness Day campaign. Leading expert on HPV infection, specialising in the 
impact of HPV on men and those living with HIV, and reducing the risk of anal 
cancer.

@askabouthpv - Instagram 
@AskAboutHPV - FB 
@AskAboutHPV - Twitter 

Hashtags: 
#askabouthpv 
#onelessworry 
#hpvawarenessday

Photo - 
https://mma.prnewswire.com/media/1758494/IPVS_International_Papillomavirus_Society.jpg

Photo - https://mma.prnewswire.com/media/1758495/IPVS_Screening.jpg 
Logo - https://mma.prnewswire.com/media/1758496/IPVS_Logo.jpg  

Source:  IPVS International Papillomavirus Society
Translations

Japanese